

**North Dakota Medicaid Drug Use Review (DUR) Board  
Meeting Minutes  
January 6, 2021**

**Members Present:** Amy Werremeyer, Andrea Honeyman, Gabriela Balf, Joshua Askvig, Laura Schield, Mary Aaland, Michael Booth, Michael Quast, Tanya Schmidt

**Medicaid Pharmacy Department:** Alexi Murphy, Brendan Joyce, LeNeika Roerich

**Announcements**

Chair A. Honeyman called the meeting to order at 1:04 p.m. The Board was notified of the open Vice-Chair position on the Board and opened the floor for nominations. A. Honeyman nominated T. Schmidt and M. Booth seconded the nomination. T. Schmidt consented to accept the nomination. No other nominations were made. The chair called for a voice vote on the position and T. Schmidt was elected unanimously by all present Board members.

**Old Business**

Chair A. Honeyman asked for a motion to approve the minutes of the September 2020 meeting. T. Schmidt moved that the minutes be approved, and JA seconded the motion. The chair called for a voice vote to approve the minutes. The motion passed with no audible dissent.

**Review Top 25 Drugs**

B. Joyce presented budget updates and the quarterly review of the top 25 drugs based on total cost od claims, as well as the top 25 drugs based on the total number of claims for the 3<sup>rd</sup> quarter of 2020.

**PDL/PA Criteria Updates**

A. Murphy shared with the Board all of changes made to the Preferred Drug List since the last version of the Preferred Drug List was posted. Notable changes included Byetta, Cosentyx, amd Repatha being added to the list of medications requiring prior authorization; removing prior authorization requirements for Toujeo Max Solostar 300 unit/mL and Tresiba 200 unit/mL when used at a dose between 100 and 200 units per day; and the removal of prior authorization requirements for coverage of Xeljanz. All PDL updates are listed in the handouts for the September 2020 DUR Board meeting. When a new version of the PDL is published and posted to the website, all updates/changes made since the last version are called out at the top of the document itself.

**Second Review of Agents for the Treatment of Diabetic Gastroparesis**

A motion and second was made at the September 2020 DUR Board meeting to place agents for the treatment of diabetic gastroparesis on prior authorization. The topic was brought up for a second review. Prior authorization criteria were presented to the Board by T. DeRuiter. There were no public comments. Chair A. Honeyman called for a voice vote to approve the updated criteria, which passed with no audible dissent.

### **Second Review of Ohriahnn (elagolix/estradiol/norethindrone)**

A motion and second was made at the September 2020 DUR Board meeting to place Ohriahnn on prior authorization. The topic was brought up for a second review. Prior authorization criteria were presented to the Board by T. DeRuiter. J. Gianninoto from Abbvie presented information on Ohriahnn and Orilissa to the Board. Chair A. Honeyman called for a voice vote to approve the updated criteria, which passed with no audible dissent.

### **Second Review of Dojolvi (trihexanoin)**

A motion and second was made at the September 2020 DUR Board meeting to place Dojolvi on prior authorization. The topic was brought up for a second review. Prior authorization criteria were presented to the Board by T. DeRuiter. T. Arnhart provided testimony on Dojolvi and made himself available to the Board for questions during public comments. Chair A. Honeyman called for a voice vote to approve the updated criteria, which passed with no audible dissent.

### **Update to Criteria for Nucala (mepolizumab) for Hypereosinophilic Syndrome & EGPA**

T. DeRuiter presented proposed updates to the prior authorization criteria for Nucala to include criteria for diagnoses of hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis (EGPA). There was no public comment. Chair A. Honeyman called for a voice vote to approve the updated criteria, which passed with no audible dissent.

### **Annual Review of Prior Authorization Forms and Criteria**

The Board reviewed all forms and criteria utilized for all medications that are currently placed on prior authorization. Notable updates to the criteria were highlighted by A. Murphy, including the listing of non-solid dosage formulation criteria; changes to prior authorization requirements for select insulin products; updates to criteria for agents used for the treatment of hepatitis C; changes to prior authorization criteria for Eucrisa; changes in preferred and non-preferred agents for the treatment of eosinophilic asthma; and updates to prior authorization criteria for agents used in the treatment of Parkinson's. A motion was made by M. Quast to approve the reviewed forms and criteria, which was seconded by A. Werremeyer. Chair A. Honeyman then called for a voice vote for approval of the reviewed forms and criteria, which passed with no audible dissent.

### **New Business**

#### **Review of Evrysdi (risdiplam)**

T. DeRuiter presented a review of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) to the Board. There was no public comment. A motion was made by A. Werremeyer to manage these medications through prior authorization. The motion was seconded by J. Askvig. Prior authorization criteria for these agents will be presented, reviewed, and voted on by the Board at the next meeting.

#### **Retrospective Drug Utilization Review (RDUR) Criteria Recommendations**

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are consistent with new indications, new drugs added, and new warnings. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. M. Booth moved to approve the new criteria and T. Schmidt seconded the motion. The motion passed with no audible dissent.

**Adjournment and Upcoming Meeting Date**

Chair A. Honeyman adjourned the meeting at 2:45 pm. The next DUR Board meeting will be held March 3, 2021 at 1:00 pm and will be held via teleconference.